UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, DC 20549
 
Amendment No. 1 to
 
FORM 8-K/A

CURRENT REPORT PURSUANT
TO SECTION 13 OR 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934

Date of Report (Date of earliest event reported): November 29, 2006

Neuro-Hitech, Inc.
(Exact Name of Registrant as Specified in its Charter)
 
Delaware
(State or Other Jurisdiction of Incorporation)

000-51887
20-4121393
(Commission File Number)
(I.R.S. Employer Identification No.)
   
One Penn Plaza, Suite 1503, New York, NY
10019
(Address of Principal Executive Offices)
(Zip Code)

(212) 594-1215
(Registrant’s Telephone Number, Including Area Code)
 
 
(Former name or former address, if changed since last report.)


Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

o
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

o
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
 
o
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

o
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4c))


Item 9.01. Financial Statements and Exhibits.

On November 29, 2006, we filed a Current Report on Form 8-K to report our November 29, 2006 acquisition by merger of Q-RNA, Inc. (“Q-RNA”). We are filing this Amendment No. 1 to the Report to include the pro forma financial information required under Item 9.01 of Form 8-K.

(d) Exhibits.

99.3
Pro forma financial information
 

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
 
     
  NEURO-HITECH, INC.
 
 		  
 		  
 
Date: February 12, 2007 By:   /s/ David Barrett
 
David Barrett
  Chief Financial Officer